A gene therapy programme is never one material at one temperature. It is a chain: plasmid DNA, producer cell banks, virus seed banks, the vector itself — most often based on adeno-associated virus (AAV) or lentivirus — and, for ex vivo therapies, the gene-modified cells that finally reach the patient.
Good viral vector storage therefore asks not "what is the right temperature?" but "which material belongs where?" — a –80 °C ultra-low temperature freezer or the vapour phase above liquid nitrogen, which tank, and what access frequency.
A wrong allocation rarely shows at once. It surfaces months later as titre loss, aggregation or a deviation in release testing — on batches that cannot simply be remade.
Viral vector storage typically spans five material classes: plasmid DNA, vector drug substance or drug product, producer cell banks and virus seed banks, gene-modified cell products, and reference standards and retained samples. Each differs in stability, storage duration and access pattern, and so in the storage condition it needs.
Most gene therapy sites therefore need both worlds: qualified –80 °C storage and LN₂ infrastructure.
For many AAV products and lentiviral vectors, a qualified –80 °C ultra-low temperature freezer is the specified and entirely adequate condition, provided stability data covers the intended storage period. Liquid nitrogen is not automatically better. Moving vector batches into LN₂ without supporting data creates new validation questions, not extra security.
The real risk lies less in the set point than in handling:
In practice: single-use aliquots, working stock physically separated from long-term reserve, and every temperature excursion assessed against the stability data.
Producer cell banks, virus seed banks and gene-modified cell products belong in the vapour phase above liquid nitrogen because they must remain functionally unchanged for many years. That requires a storage temperature reliably below the glass transition of roughly –130 °C, independent of power supply and compressor technology.
Above roughly –130 °C, water in the unfrozen matrix remains molecularly mobile, and recrystallisation and slow degradation continue. Below that threshold, molecular mobility effectively comes to a halt.
For a virus seed bank supplying identical starting material across the product lifecycle, that is decisive. A cryogenic tank also has no compressor to fail: thermal inertia and the nitrogen inside carry it for hours to days.
For viral material, vapour phase is the right choice because liquid nitrogen is not a sterile medium. In the liquid phase, pathogens can travel through the nitrogen from a leaking container to other samples.
A documented case from the 1990s, in which a virus passed this way between patient products in a liquid-phase tank, changed storage practice for good. With viral vectors the risk runs both ways: adventitious agents can reach the product, and vector material can contaminate other inventories.
Stored above the LN₂ level, samples have no liquid contact — and tank design must ensure that even the upper positions stay below roughly –130 °C.
Viral vectors and many derived materials are generally classed as genetically modified organisms (GMOs) and belong in dedicated, segregated inventories. In the EU, their contained use falls under Directive 2009/41/EC; in Germany, the Gentechnikgesetz (GenTG) and Gentechnik-Sicherheitsverordnung (GenTSV) apply, and storage explicitly counts as genetic engineering work.
German law assigns such work to four safety levels, S1 to S4. Classifying a specific vector — by vector system, inserted gene and risk assessment — is the operator's responsibility, not the storage system's. For cryogenic infrastructure, that means:
Access frequency also shapes tank allocation. Master seed banks and retained samples may stay closed for years; working stock and patient batches awaiting shipment are accessed regularly.
Every opening is a heat input into the vapour phase. If the archive shared a tank with working stock, irreplaceable material would carry the thermal load of routine operations. Separation costs one additional vessel — and removes a structural risk.
Consarctic GmbH, serving customers in more than 30 countries, supplies the cryogenic infrastructure for the LN₂-stored materials of a gene therapy programme: from controlled-rate freezing through vapour-phase storage to transport between manufacturing site and treatment centre. Where stability data specifies –80 °C, a qualified ultra-low temperature freezer remains the right answer.
Certified Consarctic technicians handle installation and qualification (IQ/OQ/PQ), including temperature mapping of released storage positions — packaged as the GMP Validation Suite. The 24/7 emergency service is available 365 days a year.
Gene therapy medicinal products are advanced therapy medicinal products (ATMPs) under Regulation (EC) No 1394/2007, and their manufacture follows the ATMP-specific GMP guidelines in EudraLex Volume 4. Consarctic GmbH is certified to EN ISO 13485:2016 and ISO 9001:2015, and all systems are manufactured to GMP-compliant standards. Roche, GSK and Bayer, along with the CDMO Minaris Regenerative Medicine, work with Consarctic systems.
Most AAV vectors are stored frozen at –60 °C or below, commonly at –80 °C. The binding condition is whatever the product's own stability data supports. Single-use aliquots help avoid repeated freeze–thaw cycles, which can reduce titre.
For long-term holdings that must supply identical starting material over the whole product lifecycle, vapour phase above liquid nitrogen is the most robust option: it keeps material reliably below the glass transition of roughly –130 °C without relying on a compressor. The specific condition follows the manufacturer's stability assessment.
Because liquid nitrogen is not sterile: in the liquid phase, pathogens can pass from a leaking container to other samples. Vapour-phase storage keeps samples above the LN₂ level with no liquid contact, protecting the product from adventitious agents and other inventories from vector material.
Yes. Under EU Directive 2009/41/EC, contained use includes storing genetically modified micro-organisms, and the German Gentechnikgesetz (GenTG) likewise counts storage as genetic engineering work. Where viral vectors and derived materials qualify as GMOs, storage location, labelling and access must match the facility's classification.
Consarctic GmbH provides GMP-compliant cryogenic infrastructure for gene therapy programmes from a single source: the BIOFREEZE® SMARTLINE controlled rate freezer with TC-Aktiv, BSD+ and BSF+ stainless steel tanks for vapour-phase storage of vials and cryobags, ASR+ dry shippers, available with data loggers, for transport, and the Consarctic® Monitoring System. Installation, IQ/OQ/PQ qualification with temperature mapping and a 24/7 emergency service are included. The company is certified to EN ISO 13485:2016 and ISO 9001:2015, and Roche, GSK, Bayer and Minaris Regenerative Medicine work with Consarctic systems.
A gene therapy programme is only as stable as the storage of its most fragile link. Allocating the material chain correctly protects titre, regulatory standing and patient supply at once: –80 °C where the stability data supports it, LN₂ vapour phase for cell banks, seed banks and cell products, and separate tanks for GMO material and archive holdings.
Building viral vector or gene therapy manufacturing, or reviewing your existing storage concept? Consarctic GmbH plans, supplies, qualifies and supports complete cryogenic infrastructure for ATMP manufacturing and gene therapy — one accountable partner from first concept to a running, GMP-validated facility. Get in touch.